Incidence and Risk Factors for Macular Hemorrhage Following Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Degeneration

Moon, Sang Woong; Oh, Jaeryung; Yu, Hyeong Gon; Cho, Hee Yoon; Song, Su Jeong

doi:10.1089/jop.2012.0148

Cited by 14 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients who were diagnosed as neovascular age-related macular degeneration (AMD), arterial hypertension was a strong risk factor for large subretinal hemorrhages,33 and antiplatelet or anticoagulant use was significantly associated with retinal or subretinal hemorrhage only in patients with hypertension 34. Previously, a significant association was reported between diabetes and hypertension with macular hemorrhage (including VH) after intravitreal injection for neovascular AMD 35. Consistently, our findings suggest the importance of cautious monitoring for VH risk in patients with AF on stroke prevention therapy with such clinical characteristics.…”

Section: Discussionmentioning

confidence: 99%

Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort

et al. 2019

View full text Add to dashboard Cite

PurposeAntithrombotic therapy could be related with nuisance bleeding. This study investigated whether vitreous hemorrhage (VH) is associated with specific types of antithrombotic medication in patients with atrial fibrillation (AF).Materials and MethodsIn the Korean National Health Insurance Service National Sample Cohort, we identified 9352 antiplatelet/anticoagulant-treated AF patients. The occurrence of VH was compared between warfarin (n=1493) and a propensity score (PS)-matched antiplatelet group (n=1493) and between warfarin (n=1493) and a PS-matched warfarin+antiplatelet group (n=1493).ResultsThe outcomes of VH were lower in the warfarin than in the matched antiplatelet (1.45 vs. 3.72 events/1000 patient-years) and matched warfarin+antiplatelet groups (1.45 vs. 6.87 events/1000 patient-years). Compared with warfarin, the risk of VH increased with antiplatelet [adjusted hazard ratio (aHR) 3.90; 95% confidence interval (CI) 1.22–12.4, p=0.022] and warfarin+antiplatelet agents (aHR 4.39, 95% CI 1.74–11.2, p=0.002). Compared with warfarin only, warfarin+antiplatelet agents increased the risk of VH in patients ≥65 years, regardless of gender and hypertension. The risk of VH was significantly higher with dual antiplatelet therapy (aHR: 5.02, 95% CI: 1.56–16.2, p=0.007) or in dual (aHR: 5.02, 95% CI: 1.74–14.5, p=0.003) or triple therapy using warfarin and antiplatelet agents than with warfarin monotherapy (aHR: 6.12, 95% CI: 1.76–21.3, p=0.004).ConclusionDual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Considering the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet agents should be avoided to prevent VH in AF patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The systemic condition of subjects was found to be an important risk factor for newly developed or increased macular hemorrhage. 15 But according to our study even-though the presence of systemic diseases increases the severity of disease, its effect on psycho-social impairment is not significant.…”

Section: Discussionmentioning

confidence: 48%

Study of psycho-social impairment in patients presenting with age related macular degeneration in a tertiary eye care hospital

et al. 2014

View full text Add to dashboard Cite

“…16 In contrast, another study reported a rate of 8% for a new or increased subretinal hemorrhage in eyes with wet AMD being treated with ranibizumab. 17 MHs have been reported in conjunction with other conditions causing subretinal hemorrhages, such as retinal arterial microaneurysms (RAMs) 18,19 and trauma. 20 –22 In the setting of trauma, it is unknown whether the MHs were typical traumatic MHs or whether the subretinal hemorrhage contributed to MH formation.…”

Section: Discussionmentioning

confidence: 99%

Full-Thickness Macular Hole Caused by Acute Subretinal Hemorrhage From Wet Age-Related Macular Degeneration

Gupta,

Lean

2023

Journal of VitreoRetinal Diseases

View full text Add to dashboard Cite

Purpose: To present a case of full-thickness macular hole (MH) that developed in association with acute subretinal hemorrhage from wet age-related macular degeneration (AMD). Methods: A retrospective observational review of a single case was performed. Results: An 84-year-old man with wet AMD presented with central vision loss and floaters and was noted to have a subretinal hemorrhage and an associated MH, which subsequently progressed to MH-associated macular detachment. The patient had a pars plana vitrectomy with internal limiting membrane peeling, gas tamponade, and prone positioning, resulting in closure of the MH and improvement in visual acuity. Conclusions: A full-thickness MH developed as a result of foveal dehiscence from an acute hemorrhage caused by choroidal neovascularization in wet AMD.

show abstract

Incidence and Risk Factors for Macular Hemorrhage Following Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Degeneration

Cited by 14 publications

References 18 publications

Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort

Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort

Study of psycho-social impairment in patients presenting with age related macular degeneration in a tertiary eye care hospital

Full-Thickness Macular Hole Caused by Acute Subretinal Hemorrhage From Wet Age-Related Macular Degeneration

Contact Info

Product

Resources

About